Literature DB >> 12084233

Intracavernosal therapy: when oral agents fail.

A Nehra1.   

Abstract

Erectile dysfunction is a common problem in men older than 40 years, and the incidence increases markedly with age. Approximately one fourth of impotent men use intracavernosal injections as a primary treatment. Since its original description in the early 1980s, injection therapy has been used safely and successfully by many men and their partners. Intraurethral and oral agents for the treatment of erectile dysfunction have been introduced over the last few years, but early reports of patient satisfaction and reproducibility of erectile rigidity have not matched those of intracavernosal therapy. Thus, injection therapy remains on the forefront of treatment options.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12084233     DOI: 10.1007/s11934-001-0041-9

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   2.862


  35 in total

Review 1.  Neural control of penile erection.

Authors:  F A Giuliano; O Rampin; G Benoit; A Jardin
Journal:  Urol Clin North Am       Date:  1995-11       Impact factor: 2.241

Review 2.  Physiology of penile erection.

Authors:  K E Andersson; G Wagner
Journal:  Physiol Rev       Date:  1995-01       Impact factor: 37.312

3.  Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure.

Authors:  T C Gerstenberg; P Metz; B Ottesen; J Fahrenkrug
Journal:  J Urol       Date:  1992-05       Impact factor: 7.450

4.  Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction.

Authors:  K K Chew; B G Stuckey; C M Earle; S S Dhaliwal; E J Keogh
Journal:  Int J Impot Res       Date:  1997-12       Impact factor: 2.896

5.  Expression of functional muscarinic acetylcholine receptor subtypes in human corpus cavernosum and in cultured smooth muscle cells.

Authors:  A M Traish; M S Palmer; I Goldstein; R B Moreland
Journal:  Receptor       Date:  1995

6.  Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.

Authors:  H Padma-Nathan; W J Hellstrom; F E Kaiser; R F Labasky; T F Lue; W E Nolten; P C Norwood; C A Peterson; R Shabsigh; P Y Tam; V A Place; N Gesundheit
Journal:  N Engl J Med       Date:  1997-01-02       Impact factor: 91.245

7.  G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells.

Authors:  A M Traish; R B Moreland; C Gallant; Y H Huang; I Goldstein
Journal:  Recept Signal Transduct       Date:  1997

8.  Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.

Authors:  S A Kaplan; R B Reis; I J Kohn; R Shabsigh; A E Te
Journal:  Urology       Date:  1998-11       Impact factor: 2.649

9.  Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.

Authors:  A Bechara; A Casabé; G Chéliz; S Romano; N Fredotovich
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

10.  Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection.

Authors:  N Kim; Y Vardi; H Padma-Nathan; J Daley; I Goldstein; I Saenz de Tejada
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more
  1 in total

Review 1.  Intracavernous pharmacotherapy for erectile dysfunction.

Authors:  Anthony J Bella; Gerald B Brock
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.